Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of alemtuzumab when given
together with combination chemotherapy and to see how well it works in treating patients with
untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as alemtuzumab, can block
cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs
used in chemotherapy also work in different ways to kill cancer cells or stop them from
growing. Giving alemtuzumab together with combination chemotherapy may be a better way to
block cancer growth.